Pharma Companies Regulations Therapies 
Drug Target Review
DECEMBER 20, 2024
Smith states, weve definitely come across people in the pharma industry who worry that AI means companies might steal our data or use it in harmful ways. As the industry gains more exposure to AIs real-world applications and the rigorous standards AI companies adhere to, trust will continue to grow.
Drug Target Review
JUNE 16, 2025
All these features make GPCRs central to regulating many vital biological processes in the body, including immune responses and inflammation, and thus especially attractive for therapeutic intervention. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Patent Watch
JANUARY 9, 2025
Enter the Contract Development and Manufacturing Organization (CDMO) a lifeline for many startups looking to bring their innovative therapies to market. The pharmaceutical landscape is evolving rapidly, with small and medium-sized biotech companies increasingly taking center stage in innovation.
Drug Target Review
MAY 26, 2025
With a particular focus on biologics, cell, and gene therapies, Galbraiths work is centred on equipping drug developers with the tools, insights, and support needed to advance their therapies from concept to clinic. We are driving rapid analytics to support the release of cell and gene therapies and other biologics.
The Pharma Data
JUNE 6, 2025
As pharma companies grapple with mounting pressure from regulators, payers, and evolving market dynamics, the CSO model offers a compelling alternative to traditional, fully in-house sales forces.
Drug Target Review
MAY 23, 2023
Therapies developed in recent decades have transformed the treatment of IBD, making hospitalisation and surgery less common. However, many patients respond poorly to corticosteroid treatment, or their immune system responds unfavourably to biological therapies, such as the development of autoimmune diseases.
H1 Blog
DECEMBER 11, 2024
In 2025, I predict that there will be global regulations requiring comprehensive diversity plans for all major markets, including the EU and EMEA. As these standards take shape, pharma companies will adopt tools and models to reach broader and more diverse participants.
Expert insights. Personalized for you.
Let's personalize your content